Show Stocks and Investing Publications • Fri, September 9, 2022
Michael Ulz Maintained (BPMC) at Hold with Increased Target to $80 on, Sep 9th, 2022
ulz-maintained-bpmc-at-hold-with-increased-target-to-80-on-sep-9th-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAIMichael Ulz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Increased Target from $65 to $80 on, Sep 9th, 2022.
Michael has made no other calls on BPMC in the last 4 months.
There are 10 other peers that have a rating on BPMC. Out of the 10 peers that are also analyzing BPMC, 2 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $57 on, Thursday, August 18th, 2022
- Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022
These are the ratings of the 8 analyists that currently disagree with Michael
- Matthew Biegler of "Oppenheimer" Maintained at Buy with Increased Target to $90 on, Tuesday, September 6th, 2022
- Eun Yang of "Jefferies" Maintained at Strong Buy with Increased Target to $84 on, Monday, August 22nd, 2022
- Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $100 on, Thursday, August 18th, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $80 on, Wednesday, August 17th, 2022
- Derek Archila of "Wells Fargo" Maintained at Sell with Increased Target to $41 on, Wednesday, August 17th, 2022
- Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022
- Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, August 3rd, 2022
- David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
Like: 👍